Figure 1 shows the transfection efficiency of three designed si-RNAs by RT-qPCR (A-C). We chose the siRNA with the highest efficiency for further experiments.We chose the siRNA with the highest efficiency for further experiments. The protein level of EIF6 was also determined for the chosen siRNA (D-E). The result of PCR electrophoresis is also shown (F).

Figure 2 shows the cell proliferation by clonogenic formation assay (A-B) and viability by MTT (C) of different LN-229 cells. It was found either si-EIF6 and apatinib significantly decreased cell proliferation and viability of LN-229 cells, while the effects were stronger when cells were treated with both si-EIF6 and apatinib.

Figure 3 presents the assessment of cell invasion ability through a Transwell assay. The results indicate a significant reduction in cell invasion of LN-229 cells upon treatment with either si-EIF6 or apatinib. Notably, the combined treatment with both si-EIF6 and apatinib exhibited more pronounced inhibitory effects on cell invasion, suggesting a synergistic impact.

Figure 4 illustrates the assessment of cell migration using a wound healing assay. The results demonstrate a significant inhibition of cell invasion in LN-229 cells when treated with either si-EIF6 or apatinib. Notably, the combined treatment with si-EIF6 and apatinib exhibited enhanced inhibitory effects on cell invasion, indicating a synergistic impact.

Figure 5 shows the cell glycolysis by testing the marker genes of GLUT1, HK1 and LDHA. It was found either si-EIF6 and apatinib remarkably down-regulated the gene expression of GLUT1, HK1 and LDHA, while the inhibitory effects were stronger when cells were treated with both si-EIF6 and apatinib.